Medivation Stock Rating Lowered by Sanford C. Bernstein (MDVN)
Medivation (NASDAQ:MDVN) was downgraded by stock analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating in a report issued on Monday, Stock Ratings News reports. They currently have a $92.00 price target on the stock, up from their previous price target of $84.00. Sanford C. Bernstein’s price objective indicates a potential upside of 15.58% from the stock’s previous close.
In other Medivation news, CFO Clarence Patrick Machado sold 40,000 shares of Medivation stock on the open market in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $75.43, for a total value of $3,017,200.00. Following the completion of the sale, the chief financial officer now directly owns 30,830 shares of the company’s stock, valued at approximately $2,325,507. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Medivation (NASDAQ:MDVN) traded down 6.36% on Monday, hitting $74.54. 2,341,909 shares of the company’s stock traded hands. Medivation has a 52 week low of $41.89 and a 52 week high of $87.46. The stock has a 50-day moving average of $70.07 and a 200-day moving average of $61.3. The company’s market cap is $5.624 billion.
Medivation (NASDAQ:MDVN) last released its earnings data on Thursday, January 30th. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.29. On average, analysts predict that Medivation will post $-0.70 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on MDVN. Analysts at Needham & Company downgraded shares of Medivation from a “buy” rating to a “hold” rating in a research note to investors on Monday. They now have a $65.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks upgraded shares of Medivation from a “neutral” rating to an “outperform” rating in a research note to investors on Thursday. They now have a $101.00 price target on the stock. Finally, analysts at UBS AG raised their EPS on shares of Medivation in a research note to investors on Wednesday, January 29th. They now have a “buy” rating and a $93.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $90.18.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.